Should I choose Kadcyla or Enhertu after residual HER2+ breast cancer?

I had lumpectomy surgery two weeks ago to move residual metaplastic carcinoma from my breast. Clear margins were achieved. My original diagnosis was stage 2B and included two types of carcinoma, DCIS and ER/PR negative HER2 positive. Ten lymph nodes were removed, one of them was cancerous. I went through 6 cycles of TCHP and I’m now facing 15 rounds of radiation. Because there was residual cancer present at the time if surgery, an additional course of 14 rounds of either KADCYLA or Enhertu is being recommended. Enhertu has a great success rate for metastatic breast cancer, which I don’t have and comes with very serious warnings. It has recently been used for patients who have residual HER+ cancer in their tumors. I am having a difficult time making this decision. The KADCYLA would reduce my risk of it coming back in 5 years to 11%, but the Enhertu would take the risk down to about 5.5%. I had a difficult time on TCHP and I can’t imagine going through another 14 rounds of any type of chemo. Interested in anyone’s experience with either of these drugs.